GRF:BME
Grifols SA Class A
€9.96
arrow_downward
-0.40%(-0.040) 1D
Sep 9, 5:36:00 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRF...
Open
€9.90
High
€10.00
Low
€9.87
Mkt. cap
6.14B
Avg. vol.
1.48M
Volume
1.45M
Dividend
2.33%
Quarterly dividend
€0.06
Ex-dividend date
Jun 30, 2026
P/E ratio
14.97
52-wk high
€12.87
52-wk low
€8.43
EPS
€0.67
Shares outstanding
426.13M
No. of employees
25K
Open
€9.90
High
€10.00
Low
€9.87
Mkt. cap
6.14B
Avg. vol.
1.48M
Volume
1.45M
Dividend
2.33%
Quarterly dividend
€0.06
Ex-dividend date
Jun 30, 2026
P/E ratio
14.97
52-wk high
€12.87
52-wk low
€8.43
EPS
€0.67
Shares outstanding
426.13M
No. of employees
25K
News stories
From web sources and news partners
AD HOC NEWS
·
18 hours ago
Grifols stock heads into the open after a 1.2 percent slide
AD HOC NEWS
·
3 days ago
Grifols stock edges lower as investors weigh recent earnings and valuation
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA Class A